GlassScriptPhysician profile
Sonia E Armijo
NPI 1619457363
$4,264.41
in general payments reported to CMS, 2019-2025
29 companies · $761 in 2025
The $761 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,365 · 2022: $1,347 · 2023: $399 · 2024: $392 · 2025: $761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,548 · Education: $5.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,547.51 |
| Education | $5.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $540.23 | 2021-2023 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $539.82 | 2021-2025 | Wainua, Breztri |
| Glaxosmithkline, LLC. | $396.09 | 2022-2025 | Arexvy, Bexsero, Shingrix |
| Abbvie INC. | $351.50 | 2021-2024 | |
| Insulet Corporation | $318.90 | 2022-2025 | Omnipod |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $306.93 | 2021-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.00 | 2021-2022 | |
| Abbott Laboratories | $194.17 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $161.39 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $155.96 | 2024-2025 | Zenpep |
| Acadia Pharmaceuticals INC | $124.98 | 2024 | Nuplazid |
| Lilly USA, LLC | $117.48 | 2021-2025 | Mounjaro, Emgality, Jardiance |
| Pfizer INC. | $102.42 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $97.64 | 2024 | Voquezna |
| Organon LLC | $85.64 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $81.14 | 2025 | |
| Amarin Pharma, INC. | $72.01 | 2021 | |
| Dexcom, INC. | $65.95 | 2021-2024 | Dexcom G6 Transmitter |
| Nestle Healthcare Nutrition INC. | $64.05 | 2021-2023 | |
| Novo Nordisk INC | $42.93 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $38.42 | 2022 | |
| Smith+Nephew, INC. | $27.70 | 2022-2025 | Collagenase Santyl |
| Merck Sharp & Dohme LLC | $23.49 | 2021 | |
| Amgen INC. | $23.11 | 2024 | Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $21.43 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $19.45 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.51 | 2022 | |
| Exact Sciences Corporation | $14.88 | 2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $13.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Armijo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.